Cargando…
The PPARγ pathway determines electrophysiological remodelling and arrhythmia risks in DSC2 arrhythmogenic cardiomyopathy
Autores principales: | Reisqs, Jean‐Baptiste, Moreau, Adrien, Charrabi, Azzouz, Sleiman, Yvonne, Meli, Albano C., Millat, Gilles, Briand, Veronique, Beauverger, Philippe, Richard, Sylvain, Chevalier, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926899/ https://www.ncbi.nlm.nih.gov/pubmed/35297182 http://dx.doi.org/10.1002/ctm2.748 |
Ejemplares similares
-
Spironolactone as a Potential New Treatment to Prevent Arrhythmias in Arrhythmogenic Cardiomyopathy Cell Model
por: Reisqs, Jean-Baptiste, et al.
Publicado: (2023) -
Deciphering DSC2 arrhythmogenic cardiomyopathy electrical instability: From ion channels to ECG and tailored drug therapy
por: Moreau, Adrien, et al.
Publicado: (2021) -
Short QT interval as a harbinger of an arrhythmogenic cardiomyopathy
por: Chevalier, Philippe, et al.
Publicado: (2021) -
Arrhythmogenic cardiomyopathy as a myogenic disease: highlights from cardiomyocytes derived from human induced pluripotent stem cells
por: Reisqs, J. B., et al.
Publicado: (2023) -
Electrophysiological basis of cardiac arrhythmia in a mouse model of myotonic dystrophy type 1
por: Ginjupalli, Vamsi Krishna Murthy, et al.
Publicado: (2023)